Group A (n = 166) | Group B (n = 103) | p-value | |
---|---|---|---|
Recipient sex, male | 103 (62.5) | 65 (63.1) | 0.862 |
Recipient age, years | 34 (11–63) | 35 (13–48) | 0.470 |
Donor sex, male | 69 (41.6) | 50 (48.5) | 0.263 |
Donor age, years | 50 (42–62) | 53 (40–65) | 0.723 |
HLA-A/B mismatch | 1.69 ± 1.02 | 1.83 ± 1.07 | 0.278 |
HLA-DR mismatch | 0.87 ± 0.64 | 0.96 ± 0.63 | 0.279 |
CNI (TAC) | 90 (54.2) | 41 (39.8) | 0.022 |
ABO-incompatible | 36 (21.7) | 24 (23.3) | 0.757 |
Plasmapheresis | 17 (10.3) | 18 (17.8) | 0.078 |
Rituximab | 36 (21.7) | 22 (21.4) | 0.949 |
WIT, min | 3 (3–4) | 4 (3–5) | 0.100 |
CIT, min | 66 (55–87) | 65.5 (52–91) | 0.333 |
Initial urine output, min | 13 (7–28) | 15 (9–29) | 0.337 |
CMV infection within 3 months | 47 (28.3) | 52 (50.5) | < 0.001 |
IS decreased after CMV infection | 61.7% (29/47) | 66.7% (34/51) | 0.608 |
3-month protocol biopsy | |||
Normal | 166 (100) | 0 (0.0) | |
Borderline changes | 0 (0.0) | 83 (80.6) | |
Subclinical acute rejection | 0 (0.0) | 20 (19.4) |